Most analysts say Celgene is cheap

It seems Celgene 's stock trades with a discount. Most of the analysts mean the stock is cheap at this level. Currently the company is being followed by 14 analysts. The recommendations are: no sells, 5 times hold and no buys. The average of the target prices for the stock equals 135,46 USD. This is around 65 percent more than the current price of 81,83 USD. The most recent recommendations for the biotech company are from Morgan Stanley , JP Morgan and Barclays .

Fair values for Celgene vary a lot

Based on the current number of outstanding shares Celgene 's market capitalization is 63,71 billion USD. The Celgene stock was the past 12 months quite unstable. Since last October the stock is 40 percent lower. This year the stock price moved between 74 and 140 dollar. Since 2008 the stock price is almost 189 percent higher.

Historical stock prices Celgene period 2007-2018

At 18.57 the stock trades 2,13 percent higher at 81,83 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.